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ISTNET was held in Zurich on 23–24 January 2014 in order 
to explore the concept of adverse outcome pathway (AOP) to 
practical DNT testing. AOPs were considered promising tools 
to promote test systems development according to regula-
tory needs. Moreover, the AOP concept was identified as an 
important guiding principle to assemble predictive integrated 
testing strategies (ITSs) for DNT. The recommendations on 
a road map towards AOP-based DNT testing is considered a 
stepwise approach, operating initially with incomplete AOPs 
for compound grouping, and focussing on key events of neu-
rodevelopment. Next steps to be considered in follow-up 
activities are the use of case studies to further apply the AOP 
concept in regulatory DNT testing, making use of AOP inter-
sections (common key events) for economic development of 
screening assays, and addressing the transition from qualita-
tive descriptions to quantitative network modelling.
Abstract A major problem in developmental neurotoxic-
ity (DNT) risk assessment is the lack of toxicological hazard 
information for most compounds. Therefore, new approaches 
are being considered to provide adequate experimental 
data that allow regulatory decisions. This process requires 
a matching of regulatory needs on the one hand and the 
opportunities provided by new test systems and methods on 
the other hand. Alignment of academically and industrially 
driven assay development with regulatory needs in the field 
of DNT is a core mission of the International STakeholder 
NETwork (ISTNET) in DNT testing. The first meeting of 
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Introduction
Significant progress has been made over the past four 
decades in characterizing the hazards of a small number 
of developmental neurotoxicants. However, little effort 
has been made to address the challenge of assessing 
potential developmental neurotoxicity of thousands of 
chemicals currently in use (Crofton et al. 2012; Judson 
et al. 2009; NRC 1984, 2007). New methods, includ-
ing computational modelling, hold great promise for 
more efficient and predictive developmental neurotox-
icity (DNT) screening. In order to define a regulatory 
need-driven road map for an integrated testing strategy 
(ITS) for DNT, effective communication and discussions 
between various stakeholders (regulators, industry and 
academia) are needed. To initiate this process, the first 
meeting of the International STakeholder NETwork (IST-
NET) was held in Zurich on 23–24 January 2014 to build 
consensus on the development and the use of in vitro, 
in silico and alternative species test methods to deliver 
useful data for regulatory decision-making. The meeting 
included 28 participants from 10 countries with a balance 
of experts in the regulation and management of risk (see 
Table 1).
During the meeting, a review of animal-based test meth-
ods currently used for developmental and adult neurotoxic-
ity evaluation for regulatory purposes led to the conclusion 
that these methods are not being routinely used due to high 
costs and the use of large numbers of animals. A new test-
ing paradigm is needed that can overcome these limitations.
In vitro/in silico modelling approaches are needed in 
order to provide value-added data for regulatory purposes, 
including:
•	 Reduction in animal numbers and animal suffering for 
testing,
•	 Reduction in testing costs,
•	 Increased testing by using high-throughput systems 
(HTSs) in order to estimate environmental hazards to 
human health from thousands of substances and mix-
tures on the market in a reasonable time frame,
•	 Improve testing of environmentally relevant mixtures to 
discriminate synergistic or antagonistic effects,
•	 Improve practical bio-monitoring of environmental media 
to detect effects of unknown contaminants that would not 
appear with analytical chemical measurements,
•	 Improve testing of the multiple physicochemical vari-
ants and size distributions of nanomaterials,
•	 Cost-effective testing of low production volume chemi-
cals, metabolites, degradation products, impurities and 
others, for which no legal data requirements can be 
established for practical reasons.
The main focus of the meeting was to discuss how regu-
latory requirements for DNT testing might be met by alter-
native approaches such as in vitro test methods, quantitative 
structure–activity relationships (QSARs), read across, and 
application of the new adverse outcome pathway (AOP) con-
cept. This paper describes the main focus of the first ISTNET 
meeting: how to increase the use of alternative sources of 
data in DNT risk assessment and risk management decisions.
Current regulatory in vivo procedures
During the development of chemicals to which humans 
may be exposed, mainly drugs and pesticide, a wide range 
of hazard studies are performed. These studies, combined 
with exposure information, allow characterization of mar-
gins of safety/exposure for humans. Regulatory studies are 
designed to allow us to complete an evaluation as possible 
of any pharmacological or toxicological effects which may 
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impact human health. The majority of these studies are 
performed in laboratory animals and comply with interna-
tional regulatory guidelines. The ultimate objective of this 
testing is to enable safer use of chemicals, through hazard 
identification and risk assessment.
Regulatory guidelines for studies that generate informa-
tion about developmental neurotoxicity have been issued 
by OECD and many national regulatory agencies (e.g. US 
EPA; Japan Ministry of Agriculture, Fisheries and Food 
[JMAFF]). The three primary OECD guidelines covering 
life stage-dependent neurotoxicity are OECD 424—neu-
rotoxicity study in rodents (OECD 1997), OECD 426—
developmental neurotoxicity study (OECD 2007) and 
OECD 443—extended one-generation reproductive tox-
icity study (OECD 2011). There is also an accompanying 
guidance document (OECD Guidance Document for Neu-
rotoxicity Testing (OECD 2004) on study design and selec-
tion of additional or alternative in vivo or in vitro test meth-
ods. The purpose of the OECD guidelines is to identify 
chemicals that permanently or reversibly affect the nervous 
system, to characterize any chemical-induced alterations in 
the nervous system and to estimate dose levels (points of 
departure) for regulatory uses. The studies mainly utilize 
rodents, with the rat being the preferred species, although 
other species may be used with justification. Specific end-
points to evaluate functional, behavioural and morphologi-
cal effects of the nervous system in all study types include:
1. Detailed clinical observations in the home cage and 
open field,
2. Neurofunctional tests including motor activity,
3. Neuropathology using perfusion-fixed tissues.
Additional testing specifically for offspring that have 
been exposed to utero and early lactation includes sensory 
function testing, sexual maturation (OECD 426 and OECD 
443), assessments of behavioural ontogeny and learning 
and memory (OECD 426).
The functional tests and clinical observations in these 
guidelines are similar to those specified in OECD Guide-
lines 407 (OECD 2008) and 408 (OECD 1998) (rodent 28- 
and 90-day repeated dose oral toxicity studies), but employ 
a larger sample size than advised by the OECD Guideline 
407, calling for more frequent evaluation of functional 
tests, and require that observations are conducted without 
the knowledge of treatment.
Typically, specific neurotoxicity studies are not required 
if there are no indications of neurotoxicity from standard 
regulatory repeat-dose toxicity tests or human data (e.g. 
EU chemical and pesticide regulations 1907/2006 and 
283/2013), but there are some national differences (e.g. 
the US EPA requires adult neurotoxicity studies for all 
pesticides). Assessment of developmental neurotoxicity in 
OECD 443 or 426 studies is usually requested when data 
from standard adult and/or reproductive toxicity studies 
Table 1  List of participating organizations at the First ISNET Meeting, 23–24 January 2014, Zurich, Switzerland
Bayer AG, Germany
Centre for Xenobiotic and Risk Research (XeRR), Zurich, Switzerland
Center for Alternatives to Animal Testing of Europe (CAAT-Europe), Konstanz, Germany
Center for Alternatives to Animal Testing of USA (CAAT-USA), Baltimore, Maryland, USA
Danish Environmental Protection Agency (Danish EPA), Copenhagen, Denmark
Environment Agency of Austria, Vienna, Austria
European Food Safety Authority (EFSA)
Federal Office of Public Health, Berne, Switzerland
Finish Centre for Alternative Methods (FICAM), Tampere, Finland
Green Tox, Zurich, Switzerland
Harland Laboratories, Itingen, Switzerland
Institute for Health and Consumer Protection, European Commission Joint Research Centre (EURL-ECVAM)
IUF—Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany
National Food Institute, Technical University of Denmark (DTU), Søborg, Denmark
Nestle AG, Switzerland
Organisation for Economic Co-operation and Development (OECD), Paris, France
Regulatory Science Association, UK
National Institute for Public Health and the Environment (RIVM), Utrecht, Netherlands
Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
University of Applied Sciences Western Switzerland, Geneva
University of Trieste, Department of Life Sciences, Trieste, Italy,
University of Lausanne, Lausanne, Switzerland
National Center for Computational Toxicology, US Environmental Protection Agency (US EPA), NC, USA
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indicate a possible concern for neurotoxicity. When guide-
line neurotoxicity studies are conducted, more detailed 
tests of nervous system function are possible (as described 
in OECD Guidance Document for Neurotoxicity Testing 
(2004), but are seldom conducted in practice. For exam-
ple, guidance on the US EPA Neurotoxicity Screening Bat-
tery for Pesticides and Chemicals (OPPTS 870.6200 and 
40 CFR 799.9620, respectively), which is closely aligned 
to OECD 424, notes that “there is no clear consensus 
concerning the use of specific behavioural tests to assess 
chemical-induced sensory, motor, or cognitive dysfunction 
in animal models”.
The comparison of data for known human neurotoxi-
cants indicates that experimental animal data, such as gen-
erated in regulatory neurotoxicity studies, are frequently 
predictive of a neurotoxic effect in humans (Chang and 
Dyer 1995; Rees et al. 1989, 1990; Schaumburg and Spen-
cer 2000). Although most clinical neurotoxicity signs can 
be reproduced in animal models using rodents, this is not 
always the case. For example, in a 90-day rat neurotoxic-
ity study (OPPTS 870.6200, equivalent to OECD 424), 
ethylbenzene produced inconsistent changes in auditory 
startle which were considered not treatment related (Li 
et al. 2010). However, several non-regulatory studies have 
reported hearing loss in rats (but not guinea pigs), with 
irreversible loss of auditory function and associated loss 
of cochlear outer hair cells; therefore, the current EU pro-
posed labelling is Specific Target Organ Toxicity Repeated 
Exposure (STOT RE 2); H373 “Warning: May cause dam-
age to hearing organs through prolonged or repeated expo-
sure” (ECHA 2012).
A detailed review of the performance of data submitted 
to the EPA using the DNT guideline (Makris et al. 2009) 
concluded that the current guideline “represents the best 
available science for assessing the potential DNT in human 
risk assessment, and data generated by DNT studies are 
relevant and reliable for this assessment”. As the studies 
include parameters that are not assessed in other guide-
line studies, the authors concluded that these guidelines 
are capable of detecting changes in the nervous system not 
found with other guidelines (e.g. sub-chronic, reproduc-
tive toxicity). However, as previously mentioned, these 
guidelines are very resource intensive in terms of animals, 
time and overall cost (Rovida and Hartung 2009; Tsuji and 
Crofton 2012) and have been used only for a very limited 
number of pesticides and industrial chemicals. This high-
lights the pressing need for alternative methodologies that 
can more rapidly and cost-effectively screen large numbers 
of chemicals for their potential to cause DNT or investigate 
mechanisms to provide information on human relevance 
(Crofton et al. 2012). Such information can be used to help 
prioritize compounds and/guide the design of further, pos-
sibly less resource-consuming in vivo tests.
Regulatory perspectives on current DNT testing
Regulatory authorities face challenges with regard to 
whether potentially hazardous substances are sufficiently 
tested for adverse effects on the nervous system, in particu-
lar the developing nervous system. For example, a recent 
comprehensive review of Grandjean and Landrigan (2014) 
raised concern about the increased frequency of neurode-
velopmental disabilities such as autism, attention deficit 
hyperactivity disorder and dyslexia among children could 
be caused by exposure to industrial chemicals, which have 
not been sufficiently tested for DNT. Other evidence comes 
from epidemiological studies that associate exposure to 
some pesticides and effects on children’s neurological 
development (Horton et al. 2011; Rauh et al. 2011, 2012). 
Although a more systematic review (Burns et al. 2013) 
failed to find strong evidence for such associations. It is 
important to note that regulatory DNT guideline studies 
have only been required for some pesticides, and pesticides 
are only a small portion of the total universe of untested 
chemicals, some of which are known or suspected devel-
opmental neurotoxicants (Grandjean and Landrigan 2006).
A major challenge for regulatory authorities is the lack 
of adequate DNT data for the thousands of chemicals in 
commerce. Historically, the problem of lack of data was 
recognized as far back as 1984 when the US National 
Academy of Science (NRC 1984) released a report on the 
status of toxicity testing and estimated that there could be 
as many as 64,000 chemicals in commerce and that the 
majority either lacked, or had inadequate test data, to esti-
mate hazard potential (Fig. 1). More recently, Judson et al. 
(Judson et al. 2009) estimated that there were approxi-
mately 20,000 high-priority chemicals based on known 
bioactivity (e.g. pesticides), high production volumes or 
widespread exposure potential (e.g. drinking water con-
taminants). Considering that only 100 or so chemicals 
have actually been tested using regulatory DNT guidelines 
(Makris et al. 2009), the challenge facing the field of DNT 
testing is daunting. An alternative to currently available 
regulatory test methods that reduces both time and costs 
while maintaining or improving our understanding of DNT 
potential is urgently needed.
Regulatory needs for DNT data
In the context of the EU regulation of chemicals (Registra-
tion, Evaluation, Authorisation and Restriction of Chemi-
cals (REACH), currently the main indications for neurotox-
icity testing refer to clinical signs, functional observational 
test battery and neuropathology in standard repeated-dose 
studies. Additional information on neurotoxicity and/or 
DNT may be required if cause for concerns appears from 
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these standard repeated-dose or reproductive toxicity stud-
ies (developmental or 1- as well as 2-generation studies) or 
related to a specific modes of action or chemical structure 
information (EU Regulation 528/2012, Annex II, 18.13.2. 
(EU 2012); EU Regulation 283/2013, Annex 5.6.2 (EU 
2013a). The legally limited regulatory requirements are 
likely due, among others, to the high costs, large animal 
numbers and the scientific dispute on the uncertainty of 
standard DNT studies (OECD 2008; Smirnova et al. 2014).
This regulatory climate contrasts with the potentially 
strict downstream consequences. Though it is not explicit 
in the legal text of the EU Classification, Labelling and 
Packaging (CLP) regulation, clear evidence of DNT, at 
least theoretically, could trigger classification as reproduc-
tive (developmental) toxicity category 1A or 1B. This clas-
sification could result in a status as a substance of very high 
concern with authorization restriction consequences. In the 
context of the Biocides and the Plant Protection Regulation 
such substances would be candidates for substitution (if the 
substance has not been excluded according to the criteria 
laid down in point 3.6.3 for PPP, Art. 4(1), BPR Art 5(1) 
c). Alternatively, a DNT concern could theoretically result 
in classification for STOT RE with (usually more limited) 
legal downstream consequences. Importantly, the Biocides 
Regulation explicitly mentions that products with DNT 
concern shall not be marketed to the general public (BPR 
Art 19(4)e). Thus, while the attention currently paid by reg-
ulators to potential DNT effects is somewhat ambivalent, 
with limited upfront data requirements, it can have impor-
tant regulatory consequences.
In vitro methods currently provide great promise as more 
cost-effective methods for rapid screening of chemicals for 
DNT potential (Bal-Price et al. 2012; Crofton et al. 2011). 
In addition, these methods are likely to provide the data 
required to prioritize the vast numbers of untested chemicals 
for further in vivo testing. The use of in vitro and in silico 
tests for DNT to trigger standard DNT animal tests without 
consideration of their intrinsic value is clearly indefensible. 
However, it should be acknowledged that in vitro/in silico 
modelling data are not yet sufficient to satisfy all regulatory 
Fig. 1  Summary of data avail-
able for conducting health-haz-
ard assessments of chemicals 
(adapted and modified from 
NRC 1984; reprinted from 
Crofton et al. 2012)
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needs. Therefore, in the short-term regulators need validated 
batteries of in vitro/in silico methods that, as far as neces-
sary, can be used to prioritize chemicals and for targeted 
in vivo follow-up studies. A common understanding of the 
uncertainties associated with new in vitro and in silico mod-
elling approaches in comparison with in vivo data should 
be developed to support validation of new in vitro/in silico 
approaches and build confidence in broader regulatory use of 
in vitro/in silico modelling data. Finally, a decision frame-
work is needed on how the in vitro/in silico data will be used 
and for what regulatory purposes (e.g. screening with the 
aim of further testing, category formation and read across of 
standard animal data) or regulation in terms of classification 
or risk assessment (Patlewicz et al. 2014).
As an initial step towards this goal, we propose the use 
of an integrated testing and evaluation platform in which 
regulatory problem formulation drives testing (Crofton 
et al. 2012) allowing more efficient use of resources, target-
ing data generation directly to regulatory need. Suggested 
criteria for an approach are listed below:
•	 A battery of in vitro test methods and in silico models is 
needed that cover all relevant key neurodevelopmental 
processes.
•	 In vitro testing systems should have some metabolic 
capacity relevant for humans.
•	 Data and models should be developed that increase reg-
ulatory confidence in extrapolation from in vitro to in 
vivo.
•	 The various regulatory uses of DNT in vitro data and in 
silico models must be considered when developing a “fit 
for purpose” validation framework
•	 QSARs predicting molecular initiating events for which 
highly reproducible in vitro test data are available may 
be more relevant than QSARs predicting apical animal 
study effects with less clear reliability and relevance.
•	 Computation DNT models are needed which discrimi-
nate in vitro effects that lead to adverse downstream 
outcomes from those for which cellular- and tissue-level 
compensatory processes preclude adverse outcomes. 
This is a key regulatory need for the establishment of 
human reference doses for risk assessments. To ensure 
that regulatory actions are based on the best available 
science, constant vigilance is needed over the rapid 
advances in neuroscience and computational modelling 
that can be incorporated into improved in in vitro and in 
silico DNT methods.
Introduction of the AOP concept
The adverse outcome pathway (AOP) concept provides a 
framework for representing existing knowledge concerning 
the linkage between the molecular initiating event (MIE) and 
an adverse outcome at the individual or population levels 
(Ankley et al. 2010; OECD 2013). This framework relies on 
understanding correlative and causal relationships between the 
MIE, in which a chemical interacts with a biological target, 
resulting in a sequential series of measurable key events (KEs), 
which are cellular, anatomical and/or functional changes in 
biological processes that ultimately result in adverse outcomes 
manifesting in an individual organisms and/or a population. 
By definition, AOPs span multiple levels of biological organi-
zation that are often depicted as linear processes. However, 
biological systems involve complex interactions between mul-
tiple processes, and thus are in reality not linear. Development 
of AOPs vary in the level of detail and linearity characterizing 
the pathways and AOPs can vary substantially, both as a func-
tion of existing knowledge and risk assessment needs. Wata-
nabe et al. (2011) provides an example of the development 
of an AOP for over activation of the kainate receptor leading 
to neuronal cell death and impairments in cognitive function. 
Earlier examples of indirect effects on the developing nervous 
system include the use of the mode-of-action (MOA) frame-
work pathway analysis for developmental neurotoxicity that 
results from disruption of thyroid hormones during foetal and 
early post-natal life (Crofton and Zoeller 2005). Ideally, cau-
sality across AOPs is approached not only in a qualitative, but 
also in a quantitative way relating exposure to the adverse out-
come (OECD 2013; Vinken 2013; Meek et al. 2014).
The limited number of DNT AOPs has hampered both 
judgement of the predictive ability and regulatory use of 
high-throughput in vitro DNT data. To address this gap, a 
EURL ECVAM-SEURAT-1 workshop was held in March 
2013 in Ispra (Italy), which applied the AOP framework to 
adverse health outcomes associated with life stage-specific 
neurotoxicity. The output of the workshop was the identifi-
cation of ten putative AOPs (Bal-Price et al. 2015) for both 
neurotoxic and developmental neurotoxic outcomes. While 
these AOPs are not yet fully described, they do function to 
stimulate more detailed AOP development via identifica-
tion of data gaps and discrimination of correlative verses 
causative relationships between KEs. This workshop report 
also highlighted that the importance of the AOP concept in 
guiding development of in vitro methods, and the use of 
resulting data streams cannot be overstated.
Perspectives on how AOP concepts inform the use of in 
vitro methods
Use of the AOP framework for chemical category 
formation
In order to understand the strength of the AOP concept in 
DNT testing, it is important to consider the tools available 
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(or under development) that will use in vitro/in silico infor-
mation. One application of in vitro methods will be to 
support chemical category formation (Roberts and Patle-
wicz 2014) not only with regard to toxicity categories but 
also more broadly such as the grouping of chemicals with 
similar structures and biological activities. This informa-
tion could then be used for regulatory read-across activi-
ties (Patlewicz et al. 2014). The AOP concept can be an 
important tool that facilitates generation of the data needed 
for the formation of chemical categories: chemicals can be 
grouped according to their MIEs, and sometimes common 
KEs. AOPs provide a strong biological/pathophysiologi-
cal rationale to compound classification, which is usually 
based on chemical structures correlated to apical endpoints 
from animal experiments. AOP-based chemical category 
formation has the potential to add a value for DNT testing 
due to the complex nature of the underlying biology that is 
currently inadequately captured by chemical category for-
mation (structure or reactivity).
Use of AOP for the incorporation of in vitro DNT data 
into integrated testing strategies
The concepts that underlie the AOP framework can guide 
more effective inclusion of in vitro test data into inte-
grated testing strategies (ITSs). For example, read-across 
and toxicity classification models can be vastly improved 
when large amounts of in vitro data are available from 
high-throughput testing. Until now, these models have been 
mainly based on limited animal data available for some 
members of a read-across group or on chemico-physical 
properties and structural chemical similarities (e.g. Cronin 
1996; Estrada et al. 2001). Much richer data sets obtained 
from in vitro bioactivity testing allows for empirically 
based correlations between chemical structure and haz-
ard in quantitative activity-hazard relationships (QAHRs) 
(OECD 2007), also sometimes referred to as quantitative 
activity–activity relationships (QAARs). Combinations of 
the quantitative structure-based models into ITSs (Hartung 
et al. 2013b), sometimes (OECD 2012a, b) also described 
as Integrated Approaches to Testing and Assessment 
(IATA) (Fig. 2), are technically demanding, but an impor-
tant goal, since it may provide a more objective and robust 
approach compared to ad hoc categories and groups formed 
based on a narrative of available data. The AOP concept 
can assist in the selection of the most important tests to use 
in IATA, reflecting more appropriate coverage of MIEs and 
KEs (Tollefsen et al. 2014). Such a testing strategy for a 
neurodevelopmental process will have to reflect different 
stages of development as well as early and late processes 
conferring to brain formation. Which and how many of the 
currently available in vitro test systems are necessary to 
cover the most important neurodevelopmental KEs in ITS 
has to be revealed by analyses of chemical testing results in 
the future.
Guidance for new approaches to validation of DNT assays
All new methods for in vitro screening, including DNT, 
require some form of evaluation of their performance. 
Demonstrating that a DNT test method or model provides 
scientifically valid information is critical for regulatory 
acceptance and use. Traditionally, validation of methods 
is based on the evaluation of the reliability, i.e. reproduc-
ibility of the method (within and between laboratories) and 
the relevance of the method, i.e. how well it predicts the 
“true” result (Hartung et al. 2004; Leist et al. 2010, 2012b; 
OECD 2005, 2013). However, it is increasingly recognized 
that for some complex endpoints, it is difficult to define 
“true” results, especially when the goal is the prediction of 
adverse outcomes in humans. Empirical data on the impact 
of environmental chemicals on health effect are very lim-
ited and usually come from retrospective rather than pro-
spective epidemiological studies. Since the aim is to sci-
entifically improve human hazard assessment, it is not the 
animal test results that should be predicted, but human toxi-
cology (Paparella et al. 2012). Moreover, while data from 
animal testing are more readily available, there remain a 
number of well-recognized uncertainties in extrapolation to 
humans. The answer to the question of how to define “true” 
results will probably come from the concept of “mechanis-
tic validation” (Balls et al. 1995; Hartung et al. 2013a; Leist 
et al. 2012a) that in essence requires defining the biological 
relevance of the pathway of toxicity (Hartung and McBride 
2011; Kleensang et al. 2014) using a few substances which 
are well characterized in humans (Kadereit et al. 2012). 
AOPs can inform this process using new DNT methods 
by mapping out the most important biological pathways 
and linking them to adverse outcomes. Of course, within- 
and between-laboratory reproducibility estimates are still 
important for validation, and hazard data should be further 
integrated with distribution estimates of cellular concentra-
tions on the basis of physiologically based toxicokinetic 
models (Blaauboer et al. 2012; Judson et al. 2011; Leist 
et al. 2012b). Mechanistic validation, based on the biologi-
cal knowledge and different precise interventions, would be 
based not only on the correlation of results of test and ref-
erence model, but on the mechanism underlying the AOP 
of DNT hazard manifestation (Hartung and McBride 2011; 
Leist et al. 2012a).
As already described by the European Validation of 
Alternative Methods (ECVAM) in 1995 (Balls et al. 1995) 
and taken up in OECD GD34, validation of any method 
should be carried out towards a specific purpose. The pur-
poses can be multifold and are not solely related to full 
replacement of the regulatory animal test. As the emphasis 
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in recent times is the development of IATA which address 
potential adverse health effects in humans, without extrapo-
lating from animal data, then the purpose of validating in 
vitro or in silico methods is typically to assess the value 
and associated uncertainty of information derived from the 
method in the context of an IATA. Moreover, if the IATA 
is based on mechanistic rationale, derived, for example, 
from knowledge described as an AOP, then the value of 
the method will be related to its (mechanistic) relevance to 
key events and the reliability (reproducibility) of the data it 
generates.
For in vitro DNT methods, validation requirement (Har-
tung et al. 2004) may be relaxed when the goal of testing 
is screening of chemical library to identify substances of 
highest concern for further testing. This approach has been 
termed screening for prioritization. Such screening exercises 
can be accomplished with high-throughput screening (HTS) 
methods. In such cases, a technical validation may be appro-
priate to establish reproducibility of the method and to verify 
its expected behaviour when exposed to endpoint-specific 
control compounds (e.g. Crofton et al. 2012). The latest pro-
posal for this field was published by a group of experts with 
regard to HTS validation (Judson et al. 2013). This group 
acknowledged the need for different validation processes 
that are “fit for purpose”, meaning that the degree and type 
of validation will vary depending on the regulatory purposes 
for which data may be used. In the end, the ability of in vitro 
test results to predict the effect of exposure on human physi-
ology must always be demonstrated. However, as human 
DNT data for environmental chemicals are sparse and test-
ing in humans is not possible, one approach towards scien-
tific validation is the comparison of human in vitro data with 
analogous rodent in vitro assays, which can then be directly 
compared to rodent in vivo data and extrapolated to the in 
vivo human (Kienhuis et al. 2009).
Interpretation and combination of test results
AOPs hold great potential to impact the manner in which in 
vitro DNT data can be interpreted. As stated earlier, AOP 
provides correlative or causative links between MIEs, KEs 
and adverse outcomes (Landesmann et al. 2013; Ankley 
et al. 2010; OECD 2013). This linkage, based on empirical 
data and biologically relevant knowledge, provides more 
Fig. 2  Chemical category formation and toxicant assessment. A tra-
ditional chemistry-driven approach of classification/category forma-
tion is based on quantitative structure–activity relationships (QSAR). 
A complementary approach uses the actual activity of a compound 
(i.e. the effect in a test system) to relate it to its potential hazard 
(QAHR). Multiple QSAR/QAHR may be combined into test batter-
ies or into integrated testing strategies (ITS)/integrated approaches 
to testing and assessment (IATA). All category formation approaches 
require some form of evaluation of their performance. This may 
take the form of a classical validation or mechanistic validation or 
merely a technical validation. Simple classification outcomes are “no 
effect”, “adverse effect” or “adaptive effect”. An adverse effect may 
be defined in different ways (left bottom). At the bottom right, dif-
ferent logical approaches to hazard prediction within the context of a 
biological pathway or AOP are indicated. In probabilistic risk assess-
ment, the likelihood of a certain hazard (p(B)) would be a function of 
the test outcome (f(A)). The orange boxes exemplify a specific choice 
of approaches that may be used in the context of test structuring 
according to the AOP concept: one may choose to take the approach 
of an ITS that is mechanistically validated. Hazard would be defined 
on the basis of the biological thresholds relevant to the key events of 
the AOP. Focus for hazard prediction would be on events that are suf-
ficient by themselves to explain/result in hazard (color figure online)
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certainty for regulatory use of in vitro DNT data. In addi-
tion, information from multiple tests for a pathway that are 
consistent, will, enhance the hazard assessment. In addi-
tion, AOPs provide a framework for the discrimination of 
in vitro changes that are adverse (e.g. toxicologically rel-
evant and predictive of the adverse outcome) from those 
that are adaptive (e.g. related to compensatory processes 
that do not lead to an adverse outcome (Boekelheide and 
Andersen 2010). Three fundamental and practically appli-
cable approaches are available to define adverse effects. A 
chemical may be classified as adverse (1) when its effect is 
beyond the noise level of inactive compounds, (2) when its 
effect is similar to that of a positive control compound or 
falls in the range of positive controls, or (3) when its effect 
is beyond a meaningful, biologically defined threshold. 
Combinations of the approaches are possible (Fig. 2).
In this context, the need to differentiate adaptive from 
adverse effects in vitro requires further discussion. The 
distinction may not be as important as actually perceived, 
especially for screening of chemicals for prioritization. 
While effect definitions that do not account for potential 
compensatory reactions will probably lead to more con-
servative toxicity estimates at the screening level, this is in 
agreement with the precautionary principle that the burden 
of proof that it is not harmful falls on those taking action. 
This may also be recognized in risk assessment by using 
different uncertainty factors. In order to decide on which 
approaches to rely on for regulatory decisions, it is essen-
tial to characterize the nature of effects found in standard 
animal testing in comparison with the uncertainty of the 
new in vitro and in silico modelling approaches. The ulti-
mate goal is to be able to characterize in vitro and in silico 
DNT information for the use in regulatory decision and to 
do so with a focus on the potential of the data to accurately 
predict adverse consequences.
Transition from apical endpoints (downstream 
consequences) to early (upstream, triggering) events 
related to toxicity
The transition of animal-based hazard assessment to non-
animal methods requires a change in the concept of toxic-
ity testing (NRC 2007; Hartung 2009; Hartung et al. 2012; 
Leist et al. 2008, 2012a, b; Smirnova et al. 2014). Animal 
testing is based on parallel assessment of apical endpoints 
(Blaauboer et al. 2012), adverse outcome measures that 
most often represent relatively late events in toxicological 
damaging cascades. In quality assurance (QA) of industrial 
production of, for example, drugs or vaccines, this would 
correspond to the principle of end product control. The 
AOP concept is radically different (Fig. 3), and in an indus-
trial QA, it would correspond to the more modern principle 
of process control, i.e. assessment of each individual step at 
which a potential quality reduction may occur. These steps 
are termed key events (KEs) in the AOP concept, and it is 
assumed that a series of KEs link the molecular initiating 
event (MIE) to the final adverse outcome (AO). KE may be 
triggered by various cellular responses such as alterations 
in signalling or metabolic pathways. Triggering of a KE is 
assumed to be necessary for the next step to occur and for 
toxicity to manifest itself. Activation of the full cascade of 
KEs is considered to be sufficient for triggering the AO. 
The use of the AOP concept for risk assessment implies the 
setting up of assays for MIEs or KEs of DNT pathways, 
to provide a consistent rationale that a given test chemical 
does or does not affect the AOP. In theory, this provides a 
scientifically sound and potentially more robust and sensi-
tive approach to toxicity testing than the use of apical end-
points in animals. However, there is still work required con-
cerning the quantitative use of the concept. The situation is 
relatively straightforward if the extent to which a MIE or 
Fig. 3  Concept of adverse outcome pathways (AOPs). A complete 
AOP spans the events linking a chemical’s structure and properties 
to the adverse outcome (AO) it triggers in an organism. The deci-
sive first step is a defined molecular initiating event (MIE), an inter-
action of the chemical with a target. This triggers cellular responses 
through metabolic and signalling pathway perturbations; these cellu-
lar responses result in changes in tissues, organs and the organism. A 
pivotal element of the concept is the assumption of key events (KE). 
Complexity may arise, when reality suggests that one KE is directly 
upstream of two or more other KE, or when one of the KE is involved 
in a feedback loop
 Arch Toxicol
1 3
KE is altered and is known to be sufficient to trigger the 
final AO (Fig. 3). It is assumed that the AO occurs only 
after a biologically meaningful overall threshold has been 
passed (Boekelheide and Andersen 2010; Ramirez et al. 
2013). However, the situation is more complex, when the 
MIE (or KE) is necessary, but not sufficient to generate and 
AO, or when feedback loops or compensatory processes 
exist between KEs. Recently, web-based applications like 
the OECD sponsored AOP-Knowledgebase (https://aopkb.
org/), the AOP-Wiki (http://www.aopwiki.org), Effecto-
pedia (http://www.effectopedia.org) and Human Toxome 
knowledgebase (http://www.humantoxome.com) have been 
developed to facilitate AOP development.
For descriptions of full DNT AOPs, anchoring informa-
tion is required: both the MIE and the AO need to be known 
(Bal-Price et al. 2015; OECD 2013). This may sound 
extremely trivial, but given the situation of DNT in humans, 
very little quantitative data are available on AO with the 
relevance to DNT, and for most neurological disorders (e.g. 
autism, ADHD, Alzheimer’s), the MIE is unknown. Moreo-
ver, it is often very difficult to relate the AO in humans to 
defined organ changes measurable in experimental systems, 
the so-called toxicity endophenotypes (Balmer and Leist 
2014; Kadereit et al. 2012; Smirnova et al. 2014). There-
fore, it is important to consider, which approaches may also 
work in an anchor-independent way (Fig. 4), and how par-
tial AOPs may be applied in DNT testing.
Developmental processes underlying the MIEs and KEs 
of DNT AOPs
The lack of knowledge of the MIEs for many DNT 
AOPs leads to the question whether one could work on 
the middle part of an AOP only and still obtain mean-
ingful information. It appears that such approaches are 
indeed already available: for instance, there are tests for 
key biological processes of neurodevelopment that can 
be measured using a variety of biochemical or neuro-
functional read-outs. The key processes in DNT include 
neural stem/progenitor cell proliferation, apoptosis, cell 
migration, cell differentiation into neurons and glia cells, 
neurite outgrowth, myelination, dendrite and synapse for-
mation, and the endpoints use either cell biological and 
biochemical endpoints or appropriate transcriptomics/
epigenetics/metabolomics methods (Balmer and Leist 
2014; Baumann et al. 2014; Gassmann et al. 2010a; Har-
rill et al. 2011; Hayess et al. 2013; Kuegler et al. 2009; 
Moors et al. 2007, 2009; Ramirez et al. 2013; Hogberg 
et al. 2013; Pallocca et al. 2013; Theunissen et al. 2012a; 
van Thriel et al. 2012; Wayman et al. 2012). Other avail-
able approaches include neuronal cultures using defined 
conditions which ensure reproducible maturation stages 
of neuronal development in vitro, similar to those 
observed in vivo (Baj et al. 2014; Cáceres et al. 2012). 
These developmental stages are defined by morphologi-
cal endpoints, such as differentiation of the axon, estab-
lishment of the apical dendrite, but also functional end-
points such as onset of spontaneous activity (Baj et al. 
2014; Hogberg et al. 2010) or conversion of GABAergic-
mediated neurotransmission from excitatory to inhibitory 
(Ben-Ari and Spitzer 2010). High-throughput analysis 
of morphological or functional endpoints is feasible by 
high-content microscopy or automated electrophysiology 
testing, respectively. Importantly, it should be noted that 
while many automated morphological or functional ana-
lytic systems have been applied to 2D neuronal cultures, 
the analysis of 3D cultures presents additional challenges 
that need still to be addressed (Alépée et al. 2014). The 
key assumption for this approach is that the KEs tested by 
these methods are considered to be predictive of adverse 
effects (Fig. 3). For example, a chemical that blocks syn-
apse formation will lead to adverse developmental neuro-
logical outcomes. However, most importantly, this con-
clusion is valid, even though the exact AO and the MIE 
are unknown (see “Interpretation and combination of test 
results” section for a discussion concerning compensatory 
processes and adverse outcomes).
Fig. 4  Anchor and context dependence of different chemical assess-
ment methods. Different approaches for hazard testing and classifica-
tion may be distinguished by their dependence on anchoring (x axis), 
i.e. relating the results to other information not delivered by the test 
method. For instance, most classical assays and models (QAHR/
QSAR) require high numbers of already known compounds for cali-
brations. In contrast to this, testing of biological processes (e.g. neu-
rite growth) does not necessitate such information. Approaches may 
also be distinguished (y axis) by the extent to which they use net-
works or simple clustering approaches to categorize information form 
multiple sources. A third dimension (z axis) distinguishes methods 
by the context dependence of the endpoint measured. For instance, 
receptor binding constants or the polarity of a compound would be 
only to a small extent dependent on the assay used. In contrast to this, 
gene expression changes triggered by a compound will depend on the 
cell type, the culture conditions and many other factors
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An additional goal in the development of DNT AOPs is 
the quantitative incorporation of developmental events or 
cellular determinants of key biological processes in a sys-
tems biology model of the cell (Hartung et al. 2012). This 
would ideally be built from knowledge of the underlying 
biology and the pathway maps (see Fig. 6 in Kleinstreuer 
et al. 2013). The information requirements and bio-infor-
matic resources needed for such an approach may be large, 
but it has been discussed that the use of such models may 
then allow better identification of developmental events and 
the design of follow-up studies that are target or tailored 
for specific purposes (Rossini and Hartung 2012). Such 
a tailored approach would then be useful for routine test-
ing. Concerning this issue, it will need to be determined, 
whether the data from tailored assays are highly context 
dependent, i.e. whether complex assay systems are required 
to model the in vivo biological context to a large extent, 
or whether more simple assays of standard cell biological 
changes and biochemical reactions would be sufficient. 
With all these considerations, it needs to be remembered 
that the strategy for in vitro-based and AOP-oriented test 
strategies will require recursive steps. For instance, an 
immediate start may be provided by the approaches that are 
relatively anchor independent (Fig. 4). With time, their use 
would provide better anchors (availability of established 
tool compounds; knowledge on AO on the tissue level) to 
allow better use of anchor-dependent approaches. In the 
same vein, the comparison of highly context-dependent 
assays with biochemically oriented test batteries may help 
to identify more simplified cell-based assays and/or a more 
relevant set of biochemical endpoints for screening pur-
poses. A second consequence of these considerations is that 
the developmental “stage dependence” is a very important 
concept of DNT AOPs and needs to be considered for the 
selection of positive and negative control substances for 
test systems.
Context dependence of DNT assays
DNT AOPs could be used to “bundle” sets of tests to bet-
ter understand how integrated systems response to multi-
ple chemical stressors. Therefore, it is important to deter-
mine how data from test methods for KE within an AOP, as 
well as between AOPs, interact or not. In vitro approaches 
may be categorized according to the extent to which they 
inform networks or simple clustering approaches to cat-
egorize information from multiple sources. For instance, 
QSAR/QAHR (Quantitative Activity-Hazard Relation-
ships) approaches are at present used in parallel and the 
tests require individual validation and respective con-
trol compounds (Fig. 2). It is not yet clear how situations 
should be handled when the results of a test battery suggest 
that certain MIEs or KEs of an AOP are triggered with high 
potency, but others with low potency. Practice and experi-
ence is needed to determine whether the last KE is the most 
relevant, or whether other decision rules should be applied. 
The situation is different for a fully integrated systems biol-
ogy approach. The entire prediction process would be net-
work based, and the performance evaluation could only be 
done for the entire set-up (Fig. 4). Notably, also within an 
ITS, individual tests might have a fundamentally different 
context dependence. We still do not know whether an ITS 
based on “biochemical/biophysical-only” assays would 
work for DNT, and different toxicological fields may have 
different requirements. For instance, acute cytotoxicity may 
be deduced from test systems that are relatively context 
independent (protein denaturation, mitochondrial inhibi-
tion or membrane permeabilization), while mapping of an 
AOP for DNT would require tests that are extremely con-
text dependent (e.g. working in a cerebellar neurons, but 
not in cortical neurons or glial cells). For the practical use 
of the AOP concept and its further development, experience 
will show how assays of different complexity and context 
dependence can be combined, and whether this will be in 
fully integrated networks or in clusters of parallel tests.
Applying DNT AOP to chemical mixtures
Mixtures are still one of the greatest unsolved conceptual 
problems in toxicology. The prediction of their toxicity has 
been mainly based on apical endpoints for the individual 
compounds. However, the AOPs for various components in 
relevant heterogeneous environmental media superimposed 
on each other. This leads to considerable uncertainties if 
the mixture toxicity is predicted just on chemical analytical 
data and individual substance toxicology. Two alternative 
approaches are offered by the use of in vitro test systems 
within the AOP concept. The first uses the lower cost and 
higher throughput of some test systems to actually test the 
hazard of mixtures themselves, instead of the individual 
components only (Cavallin et al. 2014). This is often not 
possible with animal experimentation for reasons of cost 
and logistics. The second approach puts the a priori pre-
diction of mixture effects on a more solid scientific basis. 
Research into the prediction of mixture effects of poten-
tial DNT toxicants from KE of AOP might lead to a large 
advance in safety sciences, where predictions on mixture 
effects are of high importance.
How in vitro DNT tests can be used in regulatory 
decision‑making
Because of the chemical potential to produce adverse 
health effects such as DNT, chemical hazards relevant for 
human safety need to be identified and managed. From a 
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regulatory perspective, this includes the approval of new 
chemicals for pharmaceutical, food, agricultural and/or 
industrial applications, establishing limits for chemical 
contaminants in water, air and food, handling of incidents/
crisis triggered by incidental chemical contaminations.
It is acknowledged that risk assessment plays an impor-
tant role in chemical management and regulatory decision-
making. Risk assessment is chemical specific. It compares 
exposure estimate with a health-based guidance value, 
which could be either a safe level or, if not available, an 
exposure level associated with a predetermined level of risk 
(WHO 1999).
Traditionally, the establishment of a safe level of expo-
sure (called hazard characterization) has been based on 
toxicological studies conducted according to internationally 
recognized regulatory guidelines addressing an array of end-
points (e.g. subchronic/chronic toxicity, reproductive toxic-
ity, teratogenicity and carcinogenicity). It is important to 
note that DNT studies are rarely available in classical regu-
latory toxicological databases, therefore raising the question 
of the adequacy of currently used health-based guidance 
values to cover this specific endpoint. As discussed above 
("Regulatory perspectives on current DNT testing" sec-
tion), new in vitro DNT methods (including in vitro human 
stem cell-derived models) hold great promise in generating 
mechanistic data for the thousands of untested chemicals 
(Crofton et al. 2012). This has been recently acknowledged 
by the EFSA Panel on Plant Protection Products Scientific 
Opinion on the developmental neurotoxicity potential for 
two pesticides, acetamiprid and imidacloprid (EFSA 2013). 
This panel articulated uncertainties in using in vitro studies, 
referring to the difficulties in setting health-based reference 
values, and stressing the fact that simple in vitro methods do 
not adequately model the complexity of neurodevelopmen-
tal processes. The panel acknowledged that in vitro assays 
may be regarded as complementary to animal testing, and 
as such, they could be incorporated into a DNT testing strat-
egy to obtain mechanistic information or for purposes of 
screening/prioritization. The panel encouraged the develop-
ment of criteria that would trigger submission of mandatory 
DNT studies, which could include development of an inte-
grated and cost-effective, tiered testing strategy composed 
of robust, reliable and validated in vitro assays and alterna-
tive methods complementary to the in vivo test guideline 
426 for assessing the developmental neurotoxicity potential 
of substances.
A major challenge in the use of all in vitro data, not just 
DNT data, is the uncertainty in extrapolation from in vitro 
concentrations to estimates of human exposure. Without 
estimates of human exposure, the risk assessment for many 
regulatory decisions is not possible. Judson et al. (2011) 
elaborated a framework for establishing biological path-
way altering doses by using pharmaco-dynamic in vitro 
data together with pharmacokinetic modelling data. Wet-
more et al. (2013) have developed a cost-effective model 
for estimating human daily doses from in vitro concentra-
tion, albeit with large confidence limits, and work is ongo-
ing to reduce the uncertainty in these predictions as well as 
susceptible populations (Wetmore et al. 2014). This holds 
promise for the future that in vitro derived dose levels can 
be used as point of departure (POD) to calculate margins of 
exposure (MoE) (Thomas et al. 2013). MoE, defined as the 
ratio between the POD and estimated human exposure, pro-
vide an initial insight on the level of safety concern (Schil-
ter et al. 2014) and will be invaluable in prioritizing chemi-
cals for further investigation.
A promising approach to improved confidence in the use 
of in vitro DNT data by regulators is for species-to-spe-
cies comparisons using IATA and ITS. OECD is currently 
developing a framework for the development and the use 
of IATAs, building on current activities on MOA and AOP. 
The IATA framework will provide guidance on how results 
from alternative approaches could be used and interpreted 
for characterizing (both qualitatively and quantitatively) the 
adverse effects in animals and humans and/or the environ-
ment, for the use in risk assessment and classification and 
labelling.
Based on current knowledge, available methods and 
assuming that hazard assessment must be balanced with 
management goals as well as time and resource constraints, 
in vitro DNT testing could significantly contribute to deci-
sion-making in the following ways:
•	 Reduce uncertainty in hazard estimates. In vitro DNT 
data can reduce uncertainties in hazard prediction by 
providing mechanistic data for specific chemicals, 
including extrapolation between rodents and humans. 
For example, cell-based assays analogous to key neu-
rodevelopmental processes such as neural precursor 
commitment, neuronal and glial cell migration, prolif-
eration, differentiation, synaptogenesis, neurite out-
growth, functional measurements of electrical activity, 
ratio between neuronal and glial cells provide a reli-
able mechanistic insight into a potential DNT’s effects 
(Bal-Price et al. 2012). Furthermore, these DNT spe-
cific measurements can be performed using neuronal/
glial models derived from human pluripotent stem cells 
(embryonic or induced), circumventing the complex 
issues of species specificity (Fritsche 2014; Buzanska 
et al. 2009).
•	 To establish DNT as pivotal effect by determination of 
the sensitivity of developing neuronal cells in compari-
son with other cell types.
•	 Higher sensitivity/vulnerability of neurons than other 
cell types would either trigger the need for in vivo DNT 
data or justify the application of an additional uncer-
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tainty/safety factor on an existing health-based guidance 
value derived from a traditional animal database not 
covering neurodevelopmental studies. The application 
of a factor to address uncertainty regarding DNT poten-
tial would bring confidence regarding the suitability of 
the health-based guidance value to protect infant health.
•	 To optimize in silico and in vitro approaches for haz-
ard characterization. It is increasingly acknowledged 
that the toxicological properties of in silico and in vitro 
tested chemical can be predicted based on their struc-
tural features, especially those with well-studied ana-
logues, for example, through read across (Schilter et al. 
2014; Patlewicz et al. 2014). The identification of ana-
logues is not straightforward and should focus not only 
on chemical structure, but also on mechanism of action 
and/or biological activity/property (Schilter et al. 2014; 
Wu et al. 2010). Indeed, for a group of chemical ana-
logues with members being documented as neurode-
velopmental toxicants, in vitro investigations might 
improve the selection of the most relevant analogue(s) 
to be applied in read across. This requires demonstrat-
ing that the relevant specific neurodevelopmental effect 
is modelled adequately in vitro. In addition, knowledge 
built during the development of the AOPs specific for 
DNT will facilitate the construction of chemical catego-
ries for read across according to MIEs and KEs. The 
chemical classification can be further linked to a struc-
ture activity relationship to develop QSAR models spe-
cific for DNT effects.
•	 To trigger and tailor in vivo DNT studies. In the shorter 
term, in vitro data, together with signals from manda-
tory repeat-dose studies, could improve the design of 
the in vivo studies when they would be needed for regu-
latory purposes.
Challenges in use of in vitro DNT in an AOP format
The AOP framework concept has brought novel opportu-
nities for the application of alternative methods in chemi-
cal hazard identification. The challenge of utilizing such 
alternative approaches within the AOP concept lies first 
of all in the development of AOPs for DNT. As mentioned 
above (“Introduction of the AOP concept” section), an ini-
tial effort towards creation of possible DNT AOPs from the 
currently available literature has been initiated (Bal-Price 
et al. 2015), but there is still a large body of work to be 
done for accomplishing this task. A current challenge for 
DNT testing is the need to develop in vitro tests for MIEs 
that reliably predict AOs. DNT AOPs provide the frame-
work that links MIEs to DNT AOPs via a series of KEs. 
Currently, alternative methods are evaluated individually by 
their predictivity with regard to their correct classification 
of positive and negative test compounds. When positioned 
within the AOP context, the usefulness of each assay is 
determined relatively to its place in the series of key events 
within an AOP. This approach offers the opportunity to ver-
ify that the in vitro method is part of a signalling pathway 
related to measurable KEs. For example, a pathway pre-
sent, active and responsible for a KE in vivo should also 
be similarly responsive in an in vitro assay reflecting the 
same KE. Thus, the approach of placing in vitro methods 
into individual AOP contexts will increase the reliability 
of results from such well-characterized alternative assays 
because data are obtained on a sound knowledge base with 
clear determination of individual assay’s biological appli-
cation domains. The criteria for establishing correlative and 
causative linkages in AOPs can be especially challenging in 
biological systems with high levels of biological complex-
ity, such is the DNT. The developing brain holds spatiotem-
poral peculiarities as it contains many different interacting 
cell types within a variety of cellular structures and targets 
(Lieberman et al. 2008), many of which change their func-
tion over developmental time (Ben-Ari 2002). For example, 
neural tube closure or neural progenitor cell proliferation 
are affected at earlier stages than brain cortex maturation 
(Rice and Barone 2000). Thus, different MIEs may lead to 
the same adverse outcome, and several adverse outcomes 
may be caused by the same MIE, depending on exposure 
timing and developmental stage. In addition, there is spe-
cies specificity in metabolism (Graham and Lake 2008) and 
toxicodynamics (Gassmann et al. 2010b; Heuer 2013) com-
plicating animal–human extrapolation.
This complex situation may be simplified by focus-
sing on common key events (CKEs, Fig. 5). An example 
of CKEs in DNT involve alterations in developmental pro-
cesses critical for normal brain architecture development, 
such as neural crest cell proliferation and migration, neural 
stem/progenitor cell proliferation, migration and differen-
tiation, neurite outgrowth, myelination, synapse and net-
work formation and cell–matrix interactions. Compounds 
acting on different MIEs which alter one or more of these 
common developmental processes may be especially suited 
as common transversal read-outs for an array of different 
AOPs. For these endpoints, a variety of in vitro alternative 
assays are currently established and available (Bal-Price 
et al. 2012; Baumann et al. 2014; Fritsche 2014; Theunis-
sen et al. 2012b). The challenge is for practical use of these 
CKEs in the AOP context. While they are clearly correla-
tively predictive for AOs, in that decreased number of neu-
rons, mismigration of cell, or failure of synaptogenesis is 
all indicative of altered neurodevelopment; however, the 
causative links are currently lacking. This is not a failure 
of neurotoxicology research, but instead indicative of the 
lack of known pathobiology of most developmental neuro-
logical disorders. Therefore, it is crucial to understand that 
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the state of the science currently provide the use for CKEs 
in correlative-based AOPs that allow only qualitative pre-
dictions of DNT AOs. Future research, including advances 
in developmental neurobiology, is needed, leading from 
causatively like developmental neurological signalling 
pathways to functional evaluation of brain development. 
The AOP framework empowers development of the CKE 
concept towards this goal.
A path forward for developmental neurotoxicity testing
Any vision for the future of a scientific endeavour requires 
a clear articulation of the problem(s) for which solutions 
are needed. Problem formulation in research can be both 
difficult and time-consuming. For DNT testing, many of 
the dominant and pressing problems have been well articu-
lated (Bal-Price et al. 2012; Crofton et al. 2012; Leist et al. 
2013b; Smirnova et al. 2014). These problems include the 
need to (1) screen thousands of chemicals for bioactivity 
(Fig. 1; Fund 1997; NRC 1984) and (2) develop and use 
in vitro and in silico models based on human biology (EU 
2013b; Leist et al. 2013a; NRC 2007).
Over the past decade, significant advances in the field 
of in vitro testing methods for DNT have led to the devel-
opment and characterization of a variety of cellular-based 
systems (Baumann et al. 2014; Harrill et al. 2010; Hoelt-
ing et al. 2013; Hogberg et al. 2013; Honegger et al. 2011; 
Zimmer et al. 2012) and establishment of methods employ-
ing alternative model organisms (Avila et al. 2012; Cowden 
et al. 2012; Selderslaghs et al. 2013; Truong et al. 2014). 
New cellular models for assessing an array of DNT end-
points include primary neuronal cells from rodents, human 
and rodent tumour-derived neuronal cell lines, and stem-/
progenitor cell-based neural cells from humans and rodents 
(Bal-Price et al. 2012; Crofton et al. 2012; Fritsche 2014). 
New alternative model species such as C. elgans and 
zebrafish have also been developed to study the impact of 
chemicals on the developing nervous system (Bal-Price 
et al. 2012; Crofton et al. 2012; de Esch et al. 2012; Padilla 
et al. 2011; Selderslaghs et al. 2013). More recently, the 
growing awareness that cells in a 3D context maintain 
physiological signalling much better than cells growing 
in a 2D format (Yamada and Cukierman 2007) led to the 
establishment of 3D models that recapitulate more physi-
ological neurodevelopmental functions (e.g. Fritsche 2014; 
Pamies et al. 2014; Alépée et al. 2014; Baumann et al. 
2014; Hoelting et al. 2013; Hogberg et al. 2013; Honegger 
et al. 2011; Moors et al. 2009). Recent publications also 
highlight new methods that allow for higher throughput 
testing of neuronal function in vitro using microelectrode 
arrays or “brain on a chip” technologies (Charkhkar et al. 
2014; Kapucu et al. 2012; Novellino et al. 2011; Robinette 
et al. 2011; Ylä-Outinen et al. 2010). Together these meth-
ods demonstrate significant progress in methods develop-
ment for DNT testing. However, a number of issues remain 
concerning application and predictability of such in vitro 
methods that must be addressed (Table 2).
First and foremost of the remaining issues is the need to 
implement these test methods in order to develop data that 
will allow an assessment of their utility in screening for 
DNT. The state of the science for other areas of toxicology, 
such as developmental, reproductive and endocrine toxic-
ity as well as carcinogenesis, has made immense progress. 
This includes the development of in vitro testing databases 
for hundreds of assays and thousands of chemicals in the 
ToxCast and Tox21 programs (Attene-Ramos et al. 2013; 
Kavlock et al. 2012). This has fostered development of 
computational models predicative of in vivo adverse out-
comes (Martin et al. 2011; Rotroff et al. 2013; Sipes et al. 
2011). The lack of adequate data sets for large numbers 
of chemicals from in vitro DNT assays has severely ham-
pered the development of computational models. To date, 
a limited number of in vitro assays have used small sets 
of chemicals (20–75 chemicals) (Harrill et al. 2011; Krug 
et al. 2013; Novellino et al. 2011; Zimmer et al. 2014).
These and other available assays need to be used to 
begin screening larger chemical libraries (e.g. Tox21/Tox-
Cast). However, moving from methods development to 
use in screening large sets of chemicals for DNT requires 
caution (Kadereit et al. 2012). Performance and predictive 
value of an assay requires determination of whether the 
assay is “fit for purpose” and different sets of chemicals 
may be needed depending on the use of the data (Crofton 
et al. 2011; Judson et al. 2013; Kadereit et al. 2012). 
Chemical libraries should also contain chemicals known 
or suspected of causing DNT effects. Lists of such chemi-
cals have been proposed (Grandjean and Landrigan 2014; 
Kadereit et al. 2012).
Fig. 5  Concept of common key events (CKEs). CKEs are identical to 
KEs altered within multiple AOPs. When those are chosen as testing 
endpoints, the number of assays/AOPs can be drastically reduced
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As mentioned above, another major issue in the devel-
opment and use of in vitro data for regulatory purposes is 
the lack of well-described and codified AOPs for develop-
mental neurotoxic outcomes. To date, only a limited num-
ber of peer-reviewed AOPs are available for DNT and these 
are limited to endocrine-related MIEs (Crofton and Zoeller 
2005; Zoeller and Crofton 2005).
A recent review (Bal-Price et al. 2015) has highlighted 
the need for the development of more AOPs specific for 
neurotoxic and developmental neurotoxic outcomes, and 
provides a number of putative AOPs for future develop-
ment. This lack of AOPs hampers the ability to correla-
tively or causatively link data from in vitro assays that 
target MIEs of upstream key events to adverse outcomes 
(Ankley et al. 2010). These kinds of linkages are neces-
sary to build confidence for the use in regulatory deci-
sions. Creation of AOPs for DNT must take into account 
the temporal and dose dynamics critical for neurodevelop-
ment processes. This is needed to ensure that in vitro and 
alternative species models encompass the critical processes 
necessary for brain development (Coecke et al. 2007). This 
type of approach will also assist in the targeted generation 
of missing molecular-, cellular-, tissue- and organism-level 
data using in vitro and in vivo methods to develop AOPs. 
AOP development will also foster identification of MIEs 
and/or key events in AOPs for which in vitro assays need to 
be developed.
As discussed earlier, normal development of the nervous 
system is a complex set of interactions between different 
neuronal and glial cell types and developmental processes 
that are temporally and spatially regulated (neuroepithelial 
differentiation from embryonic stem cells, neural crest cell 
migration, neural stem/progenitor cell proliferation, radial 
glia migration, differentiation into neurons and glial cells, 
neuronal migration, neurite outgrowth, dendrite develop-
ment, synaptogenesis and network formation). Therefore, 
assays, especially those employing a single cell type cul-
tures, are unlikely to be able to correctly identify DNT 
potential for all chemicals. A number of approaches are cur-
rently being pursued including development of a battery of 
assays using multiple neuronal and glial cell types (Coecke 
et al. 2007) as well as using three-dimensional multi-cell 
cultures with read-outs for multiple neurodevelopmental 
processes (Alépée et al. 2014; Baumann et al. 2014; Zurich 
et al. 2002; Monnet-Tschudi et al. 2000). Recently, new 
microfluidic organs-on-chips methods have been devel-
oped that more accurately simulate tissue- and organ-level 
physiology (Bhatia 2014). These new approaches will not 
only provide great insight into the complex dynamics of 
neurodevelopment, but also allow more realistic testing 
scenarios. More work is urgently needed to produce testing 
data that will allow comparisons of the predictive capac-
ity across assays and batteries of assays with the goal of 
developing a set of tests assembled into testing batteries 
that cover pathways and processes of brain development as 
comprehensively as possible. Development and use of bat-
teries of in vitro assays for testing chemicals will be a huge 
step forward into DNT evaluation.
Another major need for the development and the use of 
DNT in vitro methods is the generation of case studies for 
use of AOP-based DNT screening data in regulatory deci-
sions. While at the present time there may not be enough 
Table 2  Summary of actions needed to build AOP-based in vitro DNT screening tools for regulatory use
Creation of putative AOPs for DNT by taking existing data on basic molecular developmental neuroscience as well as DNT into account that 
will foster:
 Targeted generation of missing molecular-, cellular-, tissue- and organism-level data using in vitro and in vivo methods to develop validated 
AOPs
 Identification of MIEs and/or KEs in priority AOPs for which cell models/alternative organisms must be generated
Generation of chemical training and testing sets for the use in assay development and validation
Generation of data sets for large numbers of chemical that allows qualification/validation of assay use that is “fit for purpose”, including:
 Comparison of results across assays with similar endpoints
 Comparison of results of different assays across chemicals
 Development of in silico models (e.g. QSAR, docking models)
Development of a DNT alternative methods testing battery for the use in routine screening of new and existing chemicals
Development of predictive computational models based on AOPs that assess reliability of both individual test methods and the DNT testing bat-
tery, including:
 Definition of model- and endpoint-specific quantitative cut-off values for delineating adversity
 Development and incorporation of qualitative and quantitative species-specific differences in signalling pathway-driven guidance of develop-
mental processes
Generation of case studies for use of AOP-based DNT screening data in regulatory decisions, including:
 Use in multiple types of regulatory decision such as read across, prioritization for further testing and replacement of in vivo testing require-
ments
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data available, planning should begin that includes discus-
sions between assay developers, assay users and regula-
tory authorities. It is critical to engage regulators to ensure 
a fit-for-purpose approach while these methods are being 
developed. For example, regulatory authority may accept a 
higher level of scientific “uncertainty”, in both the meth-
ods and the resulting data, when making read across or 
prioritization decisions (Judson et al. 2013). Replacement 
of in vivo tests with in vitro alternatives will require that 
methods undergo a higher level of validation and result in 
data with much less uncertainty. The purpose of the current 
workshop was to begin these discussions, generate ideas 
and interactions that will foster and speed development, use 
and acceptance of alternative methods for DNT testing.
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